ONC Relative Valuation
ONC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ONC is overvalued; if below, it's undervalued.
Historical Valuation
BeOne Medicines AG (ONC) is now in the Fair zone, suggesting that its current forward PE ratio of 68.54 is considered Fairly compared with the five-year average of 79.00. The fair price of BeOne Medicines AG (ONC) is between 44.64 to 623.12 according to relative valuation methord.
Relative Value
Fair Zone
44.64-623.12
Current Price：333.87
Fair
68.54
PE
1Y
3Y
5Y
40.12
EV/EBITDA
BeOne Medicines AG. (ONC) has a current EV/EBITDA of 40.12. The 5-year average EV/EBITDA is 25.34. The thresholds are as follows: Strongly Undervalued below -57.47, Undervalued between -57.47 and -16.07, Fairly Valued between 66.74 and -16.07, Overvalued between 66.74 and 108.15, and Strongly Overvalued above 108.15. The current Forward EV/EBITDA of 40.12 falls within the Historic Trend Line -Fairly Valued range.
55.16
EV/EBIT
BeOne Medicines AG. (ONC) has a current EV/EBIT of 55.16. The 5-year average EV/EBIT is 43.91. The thresholds are as follows: Strongly Undervalued below -71.70, Undervalued between -71.70 and -13.89, Fairly Valued between 101.72 and -13.89, Overvalued between 101.72 and 159.52, and Strongly Overvalued above 159.52. The current Forward EV/EBIT of 55.16 falls within the Historic Trend Line -Fairly Valued range.
5.69
PS
BeOne Medicines AG. (ONC) has a current PS of 5.69. The 5-year average PS is 6.06. The thresholds are as follows: Strongly Undervalued below 4.23, Undervalued between 4.23 and 5.14, Fairly Valued between 6.97 and 5.14, Overvalued between 6.97 and 7.89, and Strongly Overvalued above 7.89. The current Forward PS of 5.69 falls within the Historic Trend Line -Fairly Valued range.
23.99
P/OCF
BeOne Medicines AG. (ONC) has a current P/OCF of 23.99. The 5-year average P/OCF is 73.22. The thresholds are as follows: Strongly Undervalued below -183.06, Undervalued between -183.06 and -54.92, Fairly Valued between 201.36 and -54.92, Overvalued between 201.36 and 329.50, and Strongly Overvalued above 329.50. The current Forward P/OCF of 23.99 falls within the Historic Trend Line -Fairly Valued range.
49.39
P/FCF
BeOne Medicines AG. (ONC) has a current P/FCF of 49.39. The 5-year average P/FCF is 36.49. The thresholds are as follows: Strongly Undervalued below -223.96, Undervalued between -223.96 and -93.73, Fairly Valued between 166.71 and -93.73, Overvalued between 166.71 and 296.93, and Strongly Overvalued above 296.93. The current Forward P/FCF of 49.39 falls within the Historic Trend Line -Fairly Valued range.
BeOne Medicines AG (ONC) has a current Price-to-Book (P/B) ratio of 8.33. Compared to its 3-year average P/B ratio of 6.67 , the current P/B ratio is approximately 24.90% higher. Relative to its 5-year average P/B ratio of 6.65, the current P/B ratio is about 25.39% higher. BeOne Medicines AG (ONC) has a Forward Free Cash Flow (FCF) yield of approximately 1.58%. Compared to its 3-year average FCF yield of -0.77%, the current FCF yield is approximately -304.52% lower. Relative to its 5-year average FCF yield of -0.80% , the current FCF yield is about -296.59% lower.
8.33
P/B
Median3y
6.67
Median5y
6.65
1.58
FCF Yield
Median3y
-0.77
Median5y
-0.80
Competitors Valuation Multiple
The average P/S ratio for ONC's competitors is 4.60, providing a benchmark for relative valuation. BeOne Medicines AG Corp (ONC) exhibits a P/S ratio of 5.69, which is 23.75% above the industry average. Given its robust revenue growth of 41.00%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ONC increased by 48.39% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 189.75 to 531.92.
The secondary factor is the Revenue Growth, contributed 41.00%to the performance.
Overall, the performance of ONC in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
NVDA
NVIDIA Corp
185.04USD
-2.15%
MSFT
Microsoft Corp
478.11USD
-1.11%
META
Meta Platforms Inc
646.06USD
-0.41%
AMZN
Amazon.com Inc
246.26USD
1.95%
AAPL
Apple Inc
259.04USD
-0.50%
TSLA
Tesla Inc
435.8USD
1.02%
AVGO
Broadcom Inc
332.48USD
-3.21%
ORCL
Oracle Corp
189.65USD
-1.65%
XOM
Exxon Mobil Corp
122.91USD
3.73%
WMT
Walmart Inc
113.07USD
0.31%
Frequently Asked Questions
Is BeOne Medicines AG (ONC) currently overvalued or undervalued?
BeOne Medicines AG (ONC) is now in the Fair zone, suggesting that its current forward PE ratio of 68.54 is considered Fairly compared with the five-year average of 79.00. The fair price of BeOne Medicines AG (ONC) is between 44.64 to 623.12 according to relative valuation methord.
What is BeOne Medicines AG (ONC) fair value?
ONC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of BeOne Medicines AG (ONC) is between 44.64 to 623.12 according to relative valuation methord.
How does ONC's valuation metrics compare to the industry average?
The average P/S ratio for ONC's competitors is 4.60, providing a benchmark for relative valuation. BeOne Medicines AG Corp (ONC) exhibits a P/S ratio of 5.69, which is 23.75% above the industry average. Given its robust revenue growth of 41.00%, this premium appears sustainable.
What is the current P/B ratio for BeOne Medicines AG (ONC) as of Jan 08 2026?
As of Jan 08 2026, BeOne Medicines AG (ONC) has a P/B ratio of 8.33. This indicates that the market values ONC at 8.33 times its book value.
What is the current FCF Yield for BeOne Medicines AG (ONC) as of Jan 08 2026?
As of Jan 08 2026, BeOne Medicines AG (ONC) has a FCF Yield of 1.58%. This means that for every dollar of BeOne Medicines AG’s market capitalization, the company generates 1.58 cents in free cash flow.
What is the current Forward P/E ratio for BeOne Medicines AG (ONC) as of Jan 08 2026?
As of Jan 08 2026, BeOne Medicines AG (ONC) has a Forward P/E ratio of 68.54. This means the market is willing to pay $68.54 for every dollar of BeOne Medicines AG’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for BeOne Medicines AG (ONC) as of Jan 08 2026?
As of Jan 08 2026, BeOne Medicines AG (ONC) has a Forward P/S ratio of 5.69. This means the market is valuing ONC at $5.69 for every dollar of expected revenue over the next 12 months.